An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Latest Information Update: 04 May 2023
At a glance
- Drugs LX-102-C01 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
Most Recent Events
- 04 May 2023 New trial record